Details for Patent: 5,840,763

US Patent 5,840,763: What Is Claimed and Where It Sits in the Herpes Latency Landscape

What do the claims actually cover?

US Drug Patent 5,840,763 claims a method of reducing herpes viral reactivation or reducing/eliminating establishment of latency in a human, using famciclovir or penciclovir when dosing starts late after infection.

The independent thrust is a timing limitation: administration “at greater than 18 hours post-infection.” The dependent claims then narrow by virus type, dosing regimen, and treatment windows.

Claim set (as provided)

Why the “>18 hours post-infection” limitation matters for scope

In a latency reactivation setting, competitors often argue that antiviral efficacy depends on acute-phase intervention. This patent’s core legal hook is that it still claims benefit when therapy begins after a defined post-infection threshold.

Operationally, the claim does not specify:

• route (oral/topical/systemic is not stated in the excerpt),
• adherence to a particular viral load endpoint,
• a specific virology mechanism,
• confirmation assay requirements.

So scope is anchored mainly to: 1) drug identity: famciclovir or penciclovir (or salts), and
2) start time: >18 hours post-infection (with further narrowing to ≥4 days in dependent claims), and
3) intended effect: reducing reactivation or reducing/eliminating latency establishment.

What are the key narrowing bands in the dependent claims

Virus species narrowing

• HSV-1: claims 2 and 8
• HSV-2: claims 3 and 9

This gives two clean partitions for infringement and freedom-to-operate analysis: designs for HSV-1 latency reduction do not automatically cover HSV-2 (and vice versa), though the independent claims already cover “herpes viruses” more broadly.

Timing narrowing

• Independent timing: >18 hours post-infection (claims 1 and 7)
• Dependent timing: ≥4 days post-infection (claims 5 and 11)

This creates two relevant claim “rings” for enforcement:

• the broad ring anchored at a biological cutoff (>18 hours),
• and a narrower ring anchored at a clinical cutoff (4 days).

Duration/effect window

• 3 to 14 days (claims 6 and 12)

This is a secondary constraint that limits the “length of time for reduction” in the dependent claims, which can matter if an accused regimen demonstrates delay beyond that window.

Dose and frequency narrowing for famciclovir

• dose options: 125 mg, 250 mg, 500 mg, 750 mg, 1 g
• frequency: once, twice, or three times per day

These dependent claims are important because they can be used to assert infringement for specific labeled-style regimens. They do not, however, replace the independent claims’ timing trigger.

What is the legal interpretation of “reactivation of a latent infection” in method claims

The claims are framed as treatment of latency after infection has occurred, where herpes latency exists or begins to exist and then reactivation occurs later.

The patent splits this into two method “effects”:

• Claim 1: reduces reactivation of latent herpes viruses
• Claim 7: reduces amount of or eliminates establishment of latency

In practice, this lets the patent read on two types of clinical narratives:

• a patient who already has latency and later reactivates,
• and an intervention that prevents or limits formation/establishment of latency after primary infection.

What is missing from the excerpt that would usually constrain or expand scope

The excerpt does not include:

• jurisdictional claim numbering beyond 12,
• dependent claim language about route, patient selection, baseline disease state, or diagnostic criteria,
• specific “effective amount” definitions,
• any explicit exclusions (for example, genital vs oral disease states).

Because the excerpt provides only these elements, the scope analysis rests on the stated claim text: drug identity, timing threshold, virus type, and the dependent narrowing parameters.

Where does this patent sit in the herpes antiviral patent landscape?

Core technology anchor: famciclovir/penciclovir

Famciclovir and penciclovir are nucleoside analog antivirals used against HSV and other herpesviruses. This patent does not claim the molecules; it claims a method using known drugs with a specific late post-infection timing concept in latency settings.

In a patent landscape sense, the key question is not novelty of the drug, but novelty of:

• using famciclovir/penciclovir for latency reactivation reduction,
• timing of administration relative to infection (the >18 hours anchor),
• and the clinical treatment window (≥4 days) tied to reduction duration (3-14 days).

Implications for other developers

For competing programs and method patents, the likely design-around levers are:

• using different antivirals (different drug families),
• altering timing such that administration does not fall within >18 hours post-infection,
• using drug combinations that change the claimed method’s single-drug basis,
• redefining outcomes to avoid “reactivation reduction” or “latency establishment elimination” wording.

Because the claims are method-of-treatment claims, landscape competitors typically focus on:

• endpoint framing (reactivation vs viral shedding vs symptom duration),
• clinical staging (primary infection vs established latency),
• and timing (acute vs subacute vs late post-infection).

Enforcement leverage from dependent claims

Dependent claims supply practical enforcement hooks:

• HSV-1 and HSV-2 are separately named.
• Specific famciclovir dose tiers and frequency patterns are enumerated.
• ≥4 days and 3-14 days duration windows provide concrete claim boundaries for regimen matching.

This matters for settlement value: a plaintiff can assert infringement of dependent claims if an accused product label or protocol maps closely to the dosing and timing.

Scope map: what would likely infringe vs what likely falls outside

The following is a structured scope map anchored strictly to the provided claim language.

Likely within scope

A method is within scope if it includes all of the following: 1) Drug: famciclovir or penciclovir (or salt),
2) Condition/goal: reduce reactivation of latent herpes viruses OR reduce/eliminate latency establishment,
3) Timing: administration starts >18 hours post-infection (independent), and optionally ≥4 days (dependent),
4) Virus: HSV-1 or HSV-2 for the virus-specific dependent claims,
5) Regimen mapping: dose options and frequency match for the dosing-dependent claims.

Likely outside scope

A method is outside scope if it misses a core element:

• uses a different antiviral (not famciclovir/penciclovir),
• starts therapy at or before 18 hours post-infection (for the independent timing requirement),
• does not target latency reactivation reduction or latency establishment reduction,
• lacks the duration or dosing matching needed for dependent claims (though independent claims may still be asserted).

Patent landscape considerations for US “drug patents”

Claim type and barrier to entry

This is a method-of-use style patent directed to clinical timing and outcome, using already-commercial antivirals. That structure typically creates:

• moderate technical barrier (because molecule is known),
• high legal value tied to specific timing and effect definitions.

Strategic positioning of later filings

Later patent filings in HSV latency reduction often try to avoid direct collision by:

• claiming different timing windows (acute-only or much later than the claimed windows),
• different endpoints (for example, symptomatic improvement rather than reactivation),
• different therapeutic agents,
• or different combination logic.

Because the claims explicitly anchor to >18 hours and further dependent ≥4 days, those are the first parameters later filers must align around.

Key Takeaways

• US 5,840,763 is a method-of-treatment patent covering famciclovir or penciclovir for herpes latency reduction, with the central novelty framed as administration started >18 hours post-infection (claims 1 and 7).
• Dependent claims then narrow to HSV-1 vs HSV-2, ≥4 days post-infection, 3-14 day reduction duration, and specific famciclovir dose/frequency options (125 mg to 1 g; QD/BID/TID).
• The enforcement story is anchored in matching clinical protocols to the timing trigger and latency endpoint framing; dosing details support additional claim coverage for regimens that mirror the enumerated dose bands.

FAQs

1) Does US 5,840,763 claim the molecules famciclovir or penciclovir?

No. The claims recite administering famciclovir or penciclovir; they are method claims focused on timing and latency outcomes, not composition of matter (based on the provided claim text).

2) What is the earliest post-infection time included in the independent claims?

Administration must start at greater than 18 hours post-infection (claims 1 and 7).

3) What time limitation is added in dependent claims?

Dependent claims require administration at four (4) days or greater post-infection (claims 5 and 11).

4) Are HSV-1 and HSV-2 treated separately in the claim set?

Yes. HSV-1 appears in claims 2 and 8, while HSV-2 appears in claims 3 and 9.

5) Which claims include specific famciclovir dosing ranges?

Claims 4 and 10 list famciclovir dose options 125 mg to 1 g and dosing frequency once, twice, or three times per day.

References

[1] Provided claim text for US Drug Patent 5,840,763 (user-provided).